Roche’s Alecensa latest beneficiary of faster China drug approvals

Share this post

Roche’s Alecensa lung cancer medicine became the latest beneficiary of China’s efforts to speed up approvals in the world’s second-biggest drug market, which is gaining importance for global pharmaceuticals companies’ growth plans.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply